跳至主要内容
临床试验/ACTRN12605000355673
ACTRN12605000355673已完成3 期

IBCSG 22-00 Maintenance Chemotherapy in Hormone Non-Responsive Breast Cancer withLow Dose Cytotoxics as Anti-angiogenesis treatment Following Adjuvant Induction Chemotherapy for patients with ER-negative and PgR-negative Breast Cancer

Australia and New Zealand Breast Cancer Trials Group0 个研究点目标入组 1,080 人开始时间: 2005年9月9日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
1,080

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
ot stated 至 ot stated(—)
性别
Female

入选标准

  • Premenopausal or postmenopausal patients with histologically proven, receptor-negative primary breast cancer who are in adequate health to begin or continue with induction chemotherapy, have completed baseline Quality of Life forms, are geographically accessible for follow-up and have signed written informed consent.

排除标准

  • Patients with bilateral disease, positive margins in the resected tumour specimen, previous or concomitant malignancy, patients who have received prior therapy for breast cancer, or who have non-malignant systemic diseases that would prevent them from undergoing any trial treatment options, or who are pregnant or lactating within 6 months of diagnosis.

研究者

发起方
Australia and New Zealand Breast Cancer Trials Group

相似试验